Want to see KR:011000 full AI Analyst Report?
GeneOne Life Science, Inc. (011000) AI Stock Analysis
Top Page
GeneOne Life Science, Inc.
(Korea Exchange:011000)
The score is driven primarily by very weak financial performance (shrinking revenue, negative gross profit, persistent losses, and ongoing cash burn) alongside a deteriorating balance sheet with rising leverage. Technicals also remain weak with the stock below key long-term moving averages and negative MACD; valuation provides limited support due to negative earnings and no indicated dividend yield.
GeneOne Life Science, Inc. (011000) vs. SPDR S&P 500 ETF (SPY)
- Market Cap
- KRW 48.51B
- Dividend Yield
- ―
- Average Volume (3M)
- ―
- Price to Earnings (P/E)
- -0.2
- Beta (1Y)
- 0.18
- Revenue Growth
- -64.38%
- EPS Growth
- 10.38%
- Country
- KR
- Employees
- 46
- Sector
- General
- Sector Strength
- 55
- Industry
- Biotechnology
GeneOne Life Science, Inc. Business Overview & Revenue Model
Company Description
GeneOne Life Science, Inc., a biopharmaceutical firm headquartered in Seoul, South Korea, was founded in 1976. The company focuses on the innovation and manufacturing of gene-based biomedical products. Its developmental pipeline features several cand...
GeneOne Life Science, Inc. Financial Statement Overview
Summary
Financials are highly stressed: revenue has been declining (including a steep drop in 2025), profitability is deeply negative with negative gross profit in 2024–2025, and operating/free cash flow remain consistently negative (ongoing cash burn). The balance sheet has also deteriorated with sharply higher leverage (debt-to-equity rising to ~0.81 in 2025), reducing financial flexibility despite equity remaining positive.
Income Statement
12Very NegativeBalance Sheet
38NegativeCash Flow
20Very Negative| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 18.01B | 23.93B | 35.72B | 40.20B | 48.72B | 38.70B |
| Gross Profit | -14.29B | -21.43B | -10.87B | -7.76B | 9.34B | 8.76B |
| EBITDA | -26.25B | -28.60B | -28.64B | -63.70B | -25.32B | -6.51B |
| Net Income | -41.21B | -47.66B | -48.54B | -77.77B | -38.15B | -15.95B |
Balance Sheet | ||||||
| Total Assets | 131.29B | 119.21B | 151.33B | 151.01B | 222.87B | 249.50B |
| Cash, Cash Equivalents and Short-Term Investments | 6.82B | 3.21B | 1.75B | 9.99B | 45.60B | 107.40B |
| Total Debt | 34.15B | 32.96B | 27.13B | 17.16B | 19.67B | 18.40B |
| Total Liabilities | 80.13B | 78.31B | 65.73B | 39.52B | 41.40B | 44.04B |
| Stockholders Equity | 51.15B | 40.90B | 85.61B | 111.49B | 181.47B | 206.51B |
Cash Flow | ||||||
| Free Cash Flow | -15.91B | -16.55B | -19.42B | -27.40B | -69.52B | -87.37B |
| Operating Cash Flow | -15.88B | -16.52B | -16.06B | -21.74B | -24.11B | -4.85B |
| Investing Cash Flow | -1.97B | -769.89M | -2.85B | 25.89B | 8.06B | -146.40B |
| Financing Cash Flow | 21.97B | 17.45B | 10.96B | -8.29B | 7.01B | 111.02B |
GeneOne Life Science, Inc. Technical Analysis
Price Trends
Market Momentum
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For KR:011000, the sentiment is Negative. The current price of 2670.00 is equal to the 20-day moving average (MA) of 2670.00, equal to the 50-day MA of 2670.00, and below the 200-day MA of 4600.07, indicating a neutral trend. The MACD of -2.31 indicates Negative momentum. The RSI at 27.53 is Positive, neither overbought nor oversold. The STOCH value of 0.00 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for KR:011000.
GeneOne Life Science, Inc. Peers Comparison
Overall Rating
KR:00569070Outperform
KR:95021045Neutral
KR:19980043Neutral
KR:30244043Neutral- KR:01100041Neutral
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| KR:005690 | 70Outperform | KRW 563.92B | 12.12 | ― | 0.53% | 51.28% | 124.70% |
| Sector * | 55Neutral | $6.65B | 3.83 | -15.92% | 6.20% | 10.91% | 7.18% |
| KR:950210 | 45Neutral | KRW 241.59B | -2.61 | ― | ― | 84.72% | -480.97% |
| KR:199800 | 43Neutral | KRW 285.35B | -16.97 | ― | ― | 116.74% | -482.50% |
| KR:302440 | 43Neutral | KRW 2.57T | -30.71 | ― | ― | 23.25% | -58.35% |
| KR:011000 | 41Neutral | KRW 48.51B | -0.23 | ― | ― | -64.38% | 10.38% |
* General Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| KR:011000 | GeneOne Life Science, Inc. | 2670.00 | -7555.00 | -73.89% | |
| KR:005690 | Pharmicell Co., Ltd | 9400.00 | -8738.31 | -48.18% | |
| KR:0126Z0 | Samsung Epis Holdings Co., Ltd. | 309500.00 | -129000.00 | -29.42% | |
| KR:199800 | ToolGen Incorporated | 29200.00 | -25684.21 | -46.80% | |
| KR:302440 | SK bioscience Co.,Ltd. | 32750.00 | -18050.00 | -35.53% | |
| KR:950210 | Prestige BioPharma Limited Korean Deposit Receipt Repr 1/5 Sh | 4020.00 | -8280.00 | -67.32% |
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
Date of analysis: Oct 28, 2026